Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
International Journal of Cancer|September 9, 2025
Loss of METTL3 m6A methyltransferase results in short-term progression and poor treatment outcome of bladder cancer patientsKaterina-Marina Pilala, Stella Koroneou, Maria-Alexandra Papadimitriou, et al.Blood Cancer Journal|March 16, 2025
Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcomeKonstantinos Soureas, Panagiotis Malandrakis, Maria-Alexandra Papadimitriou, et al.The Journal of Biological Chemistry|June 29, 2026
Epigenetic silencing of miR-141 via core promoter methylation is associated with short-term bladder cancer progressionKaterina-Marina Pilala, Artemis-Melina Papadimitriou, Maria-Alexandra Papadimitriou, et al.British Journal of Cancer|May 4, 2026
Delving into tRNA-derived small RNAs in multiple myeloma: elevated 3'U-tRFSerTGA leads to poor disease prognosisKonstantinos Soureas, Panagiotis Malandrakis, Maria-Alexandra Papadimitriou, et al.Molecular Therapy. Oncology|July 5, 2024
CDKN2A copy number alteration in bladder cancer: Integrative analysis in patient-derived xenografts and cancer patientsMaria-Alexandra Papadimitriou, Katerina-Marina Pilala, Konstantina Panoutsopoulou, et al.Journal of Translational Medicine|April 6, 2023
miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myelomaMaria-Alexandra Papadimitriou, Konstantinos Soureas, Aristea-Maria Papanota, et al.British Journal of Haematology|February 28, 2024
Small RNA-seq and clinical evaluation of tRNA-derived fragments in multiple myeloma: Loss of mitochondrial i-tRFHisGTG results in patients' poor treatment outcomeKonstantinos Soureas, Maria-Alexandra Papadimitriou, Panagiotis Malandrakis, et al.British Journal of Cancer|October 31, 2021
miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcomeMaria-Alexandra Papadimitriou, Aristea-Maria Papanota, Panagiotis G Adamopoulos, et al.International Journal of Molecular Sciences|December 10, 2021
A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple MyelomaAristea-Maria Papanota, Paraskevi Karousi, Christos K Kontos, et al.Pageof 2